Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10932)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22242)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (642)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22265)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030
    Meeting Abstract

    Marta, G. N.; Chu, X.; Mukhopadhyay, S.; Abramson, V. G.; Brufsky, A.; Stringer-Reasor, E. M.; Dent, S. F.; Traina, T. A.; Carey, L. A.; Rimawi, M. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study
    Meeting Abstract

    Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Pegram, M. D.; Calfa, C.; Chen, C.; Cortés Salgado, A.; Heeke, A. L.; Kang, I.; Pistilli, B.; Pohlmann, P. R.; Rugo, H. S.; Saura, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
    Meeting Abstract

    Tung, N. M.; Robson, M. E.; Nanda, R.; Li, T.; Vinayak, S.; Shah, P. D.; Khoury, K.; Kimmick, G. G.; Santa-Maria, C. A.; Brufsky, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Li, J.; Chi, P.; Kang, Y. K.; Cao, H.; George, S.; Zhang, J.; Zhang, J.; Hu, K.; Zhang, L. J.; Xu, Y. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study
    Meeting Abstract

    Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with (177)Lu-PSMA-617 versus change of ARPI in PSMAfore
    Meeting Abstract

    De Bono, J. S.; Morris, M. J.; Sartor, O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Azad, A.; Musto, C.; Netanel, S.; Zhang, T.; Rathkopf, D. E.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Runcie, K.; Dos Santos, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save